MedTrace Logo

The Effect of Sumatriptan and Placebo on CGRP Induced Headache

NCT03542357 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-09-12

No results posted yet for this study

Summary

To develop a pragmatic migraine model the investigators will induce headache in healthy volunteers and in patients with migraine without aura with aCalcitonine Gene Related Peptide (CGRP). If the headache responds to sumatriptan, the model can be used to test new drug candidates.

Conditions

Interventions

DRUG

Calcitonin Gene Related Peptide

CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

DRUG

Sumatriptan 50 mg

CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

DRUG

Placebo Oral Tablet

CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-02-15
Primary Completion
2018-09-01
Completion
2018-09-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542357 on ClinicalTrials.gov